

**Title:** One-carbon metabolism-related compounds are associated with epigenetic aging biomarkers: Results from National Health and Nutrition Examination Survey (NHANES) 1999-2002

**Authors:** Anne Bozack,<sup>1</sup> Dennis Khodasevich,<sup>1</sup> Jamaji C. Nwanaji-Enwerem,<sup>2</sup> Nicole Gladish,<sup>1</sup> Hanyang Shen,<sup>1</sup> Saher Daredia,<sup>3</sup> Mary Gamble,<sup>4</sup> Belinda L. Needham,<sup>5</sup> David H. Rehkopf,<sup>1,6,7,8,9</sup> Andres Cardenas<sup>1,8</sup>

**Affiliations:** 1. Department of Epidemiology and Population Health, Stanford University, Palo Alto, CA, US

2. Department of Emergency Medicine, Center for Health Justice, and Center of Excellence in Environmental Toxicology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, US

3. Department of Epidemiology, School of Public Health, University of California, Berkeley, Berkeley, CA, US

4. Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY, US

5. Department of Epidemiology, University of Michigan, Ann Arbor, Michigan, US

6. Department of Health Policy, Stanford University, Palo Alto, CA, USA

7. Department of Medicine - Primary Care and Population Health, Stanford University, Palo Alto, CA, US

8. Department of Pediatrics, Stanford University, Palo Alto, CA, USA

9. Department of Sociology, Stanford University, Palo Alto, CA, USA

**Sources of support:** AKB is supported by the National Institutes of Health (NIH) grant K99ES035109. JNE and AC are supported by the NIH grant R01ES031259. This research was also supported by the National Institute on Minority Health and Health Disparities (R01MD011721, MPI: BLN and DHR; and R01MD016595). The funders had no role in the decision to publish, preparation, review, or approval of the manuscript.

**Corresponding author:** Anne K. Bozack; 1701 Page Mill Rd., Palo Alto, CA, 94304; abozack@stanford.edu

**Abbreviations:** ADM: adrenomedullin; B2M:  $\beta$ -2 microglobulin; BKMR: Bayesian Kernel Machine Regression; BMI: body mass index; BMIQ: beta mixture quantile; CI: confidence interval; CpG: cytosine-guanine dinucleotide; CRP: C-reactive protein; CVD: cardiovascular disease; DNAmTL: DNA methylation telomere length; DunedinPoAm: Dunedin Pace-of-Aging; EAD: epigenetic age deviation; Hcy: homocysteine; HHS: Department of Health and Human Services; GDF-15: growth differentiation factor 15; MAE: median absolute error; MMA: methylmalonic acid; NCHS: National Center for Health Statistics; NHANES: National Health and Nutrition Examination Survey; OCM: one-carbon metabolism; PAI-1: plasminogen activation inhibitor 1; PIR: poverty to family income ratio; QC: quality control; RBC: red blood cell; SAH: S-adenosylhomocysteine; SAM: S-adenosylmethionine; SD: standard deviation; TIMP-1: tissue inhibitor metalloproteinase 1; US: United States

1 **Abstract**

2 *Background:* One-carbon metabolism (OCM), a biochemical pathway dependent on  
3 micronutrients including folate and vitamin B12, plays an essential role in aging-related physiological  
4 processes. DNA methylation-based aging biomarkers may be influenced by OCM.

5 *Objective:* This study investigated associations of OCM-related biomarkers with epigenetic aging  
6 biomarkers in the National Health and Nutrition Examination Survey (NHANES).

7 *Methods:* Blood DNA methylation was measured in adults aged  $\geq 50$  years in the 1999-2000 and  
8 2001-2002 cycles of NHANES. The following epigenetic aging biomarkers were included: Horvath1,  
9 Horvath2, Hannum, PhenoAge, GrimAge2, DunedinPoAm, and DNA methylation telomere length  
10 (DNAmTL). We tested for associations of serum folate, red blood cell (RBC) folate, vitamin B12,  
11 homocysteine, and methylmalonic acid concentrations with epigenetic age deviation (EAD) among 2,346  
12 participants with epigenetic and nutritional status biomarkers using survey weighted general linear  
13 regression models adjusting for sociodemographics, BMI, and behavioral factors.

14 *Results:* A doubling of serum folate concentration was associated with -0.82 years (95%  
15 confidence interval (CI) = -1.40, -0.23) lower GrimAge EAD, -0.13 SDs (-0.22, -0.03) lower  
16 DunedinPoAm, and 0.02 kb (0.00, 0.04) greater DNAmTL EAD. Associations were attenuated after  
17 adjusting for smoking status and alcohol intake, folate antagonists. Conversely, a doubling in  
18 homocysteine concentration was associated with 1.05 years (0.06, 2.04) greater PhenoAge EAD, 1.93  
19 years (1.16, 2.71) greater GrimAge2 EAD, and 0.26 SDs (0.10, 0.41) greater DunedinPoAm.  
20 Associations with GrimAge2 EAD and DunedinPoAm were robust to alcohol and smoking adjustment.

21 *Conclusions:* In a nationally representative sample of U.S. adults, greater folate, a carbon donor,  
22 was associated with lower EAD, and greater homocysteine, an indicator of OCM deficiencies, was  
23 associated with greater EAD; however, some associations were influenced by smoking status. Future  
24 research should focus on high-risk populations. Randomized controlled trials with long-term follow-up  
25 are also needed to establish causality and investigate the clinical relevance of changes in EAD.

26

- 27 **Keywords:** one-carbon metabolism, epigenetic aging, DNA methylation, folate, homocysteine, vitamin
- 28 B12, National Health and Nutrition Examination Survey (NHANES)

## 29 **Background**

30 One-carbon metabolism (OCM) is a biochemical pathway essential for supporting many  
31 physiological processes. OCM produces the universal methyl donor *S*-adenosylmethionine (SAM), a  
32 cofactor for methylation of DNA, proteins, amino acids, and other small molecules. OCM also includes  
33 the transsulfuration pathway, which generates the antioxidant glutathione, and provides one-carbon units  
34 for purine and thymidylate biosynthesis. OCM plays an essential role in aging-related processes by  
35 supplying methyl groups, producing building blocks for DNA synthesis and repair, and maintaining redox  
36 balance in cells.<sup>1</sup> Deficiencies or imbalances in OCM increase the risk of aging-related physiological  
37 changes and diseases<sup>1-3</sup> and may influence aging-related biomarkers.

38 OCM is dependent on diet-derived micronutrients including folate (vitamin B9) and cobalamin  
39 (vitamin B12)<sup>4</sup> (**Figure 1**; adapted from<sup>5</sup>). Naturally occurring folates are found in foods such as  
40 vegetables, fruits, legumes, and nuts. Folic acid is a synthetic, stable form of folate used in supplements  
41 and fortified foods. Folate facilitates the recruitment of methyl groups to OCM, which are subsequently  
42 used to remethylate homocysteine (Hcy) to methionine, the precursor of SAM, by methionine synthase  
43 using B12 as a cofactor. Upon donation of a methyl group, SAM is converted to *S*-adenosylhomocysteine  
44 (SAH), a product inhibitor of most methylation reactions, which can be hydrolyzed to Hcy and  
45 remethylated to methionine given adequate folate and B12. B12 is also involved in the metabolism of  
46 methylmalonic acid (MMA), a byproduct of propionate metabolism.<sup>6</sup> High Hcy concentration is an  
47 indicator of folate or B12 deficiency, and high MMA concentration is an indicator of B12 deficiency.<sup>7,8</sup>

48 The prevalence of folate and B12 deficiencies increases with age due to changes in diet, intestinal  
49 absorption, and use of antagonistic therapeutic drugs.<sup>9,10</sup> Low folate levels, which can have mutagenic  
50 effects due to reduced thymidylate biosynthesis and increased uracil misincorporation,<sup>11</sup> have been  
51 associated with age-related conditions, including dementia,<sup>12</sup> cognitive function,<sup>13</sup> and cancers.<sup>14,15</sup> Folate  
52 and B12 deficiencies also contribute to disease risk by increasing Hcy concentration. Hcy can induce  
53 oxidative stress, inflammation, and impaired endothelial function.<sup>16</sup> Elevated Hcy has been associated  
54 with increased risk of cardiovascular disease (CVD) incidence and mortality,<sup>17</sup> cognitive impairment and

55 decline,<sup>18</sup> particularly in groups with existing neurological disorders,<sup>19–21</sup> and all-cause mortality,<sup>17</sup>  
56 although associations may vary by population due to differences in diet, age, and genetic factors.<sup>22</sup>

57 In recent years, the study of aging and the healthspan has advanced with the development of  
58 epigenetic aging biomarkers, also known as epigenetic clocks. These biomarkers leverage DNA  
59 methylation levels at specific cytosine-guanine dinucleotides (CpG sites) that change with age. This  
60 phenomenon has been leveraged to train epigenetic clocks as linear combinations of DNA methylation  
61 levels at age-related CpGs. Epigenetic clocks can be broadly classified as predictors of chronological age  
62 (*i.e.*, first-generation clocks),<sup>23,24</sup> aging-related phenotypes and mortality risk (*i.e.*, second-generation  
63 clocks),<sup>25–27</sup> and rate-of-aging (*i.e.*, third generation clocks).<sup>28</sup> Epigenetic age deviation (EAD), or the  
64 difference between epigenetic and chronological age, is strongly associated with cognitive impairment,  
65 dementia, BMI, cancer, CVD, other morbidities, and all-cause mortality.<sup>29,30</sup> Second generation clocks  
66 have proven to be particularly strong predictors of cancer, CVD, comorbidity, and time to death<sup>25,27</sup> —  
67 aging-related outcomes that may have etiologies related to OCM deficiencies.

68 Testing the relationship between markers of OCM and EAD can advance our understanding of  
69 how nutritional factors and OCM function are related to complex aging- and disease-related processes and  
70 can inform the application of epigenetic aging biomarkers in research and clinical settings. In this study, we  
71 aimed to investigate associations of OCM-related micronutrients and biomarkers with EAD among  
72 participants in the National Health and Nutrition Examination Survey (NHANES), a nationally  
73 representative sample of adults in the United States (US). Our study focused on concentrations of the B  
74 vitamins folate and B12, Hcy, and MMA and seven epigenetic aging biomarkers (Horvath1,<sup>23</sup> Horvath2,<sup>24</sup>  
75 Hannum,<sup>31</sup> PhenoAge,<sup>25</sup> GrimAge2,<sup>26</sup> DunedinPoAm,<sup>28</sup> and DNA methylation telomere length  
76 (DNAmTL)<sup>32</sup>). We hypothesized that promoters of OCM (*i.e.*, folate and B12) would be associated with  
77 lower EAD, whereas indicators of OCM deficiencies (*i.e.*, Hcy and MMA) would be associated with  
78 increased EAD.

79

80 **Methods**

81 *Study population*

82 We leveraged data from the 1999-2000 and 2001-2002 cycles of NHANES. NHANES is an  
83 ongoing program conducted by the National Center for Health Statistics (NCHS) that includes interviews,  
84 physical exams, and laboratory measurements and is designed to evaluate and monitor the health and  
85 nutrition among noninstitutionalized adults and children in the US.<sup>33</sup> In the 1999-2000 and 2001-2002  
86 cycles of NHANES, DNA methylation was measured in blood samples of a subset of adults aged 50 years  
87 or older. To protect participant confidentiality, participants  $\geq 85$  years were top coded as 85 years old.  
88 Consequently, all participants assigned an age of 85 years were excluded from our analyses as we were  
89 unable to determine their true chronological age. Our study included 2,346 adults with available DNA  
90 methylation data and nutritional biomarkers after excluding sex-mismatches and participants 85 years and  
91 older (**Supplemental Figure 1**). All participants provided written informed consent, and the study  
92 protocols were approved by the NCHS Research Ethics Review Board.<sup>34</sup>

93 *DNA methylation*

94 A detailed description of DNA methylation laboratory methods and data processing can be found  
95 on the NHANES website.<sup>35</sup> In the 1999-2000 and 2001-2002 cycles of NHANES, DNA methylation was  
96 measured in blood samples of 2,532 adults. Samples were selected for DNA methylation measurement  
97 among participants aged 50 years or older with available biospecimens and included a random sample of  
98 approximately half of eligible non-Hispanic White participants and all eligible participants from other  
99 ethnic and racial groups (*i.e.*, non-Hispanic Black, Mexican American, other Hispanic, and other race).<sup>35</sup>  
100 DNA was extracted from whole blood and stored at  $-80^{\circ}\text{C}$  until DNA methylation measurement. DNA  
101 underwent bisulfite conversion and DNA methylation was measured using the Illumina Infinium  
102 MethylationEPIC BeadChip v1.0 (Illumina, San Diego, CA, US) following the manufacturer's  
103 recommendations. The MethylationEPIC BeadChip interrogates over 850,000 CpG dinucleotides.<sup>36</sup> Raw  
104 DNA methylation data were imported into R for preprocessing and quality control (QC). The

105 preprocessing and QC pipeline included color correction, background subtraction, and removal of outlier  
106 samples based on median intensity values.

### 107 *Epigenetic age and biomarkers*

108 Epigenetic age estimates and aging biomarkers were provided by NHANES.<sup>35</sup> Prior to biomarker  
109 calculation, DNA methylation data were normalized using the beta mixture quantile (BMIQ) method,  
110 which adjusts for probe type bias.<sup>37</sup> For the calculation of the Horvath1, Horvath2, PhenoAge, and  
111 GrimAge2 clocks, a modified BMIQ method was applied using a gold standard based on the largest  
112 training dataset in the Horvath1 clock.<sup>23</sup> The epigenetic age estimates or scores were calculated for each  
113 participant using the respective published coefficients and intercepts. We focused on widely studied and  
114 established epigenetic aging biomarkers including three first-generation clocks (*i.e.*, trained to estimate  
115 chronological age): Horvath1,<sup>23</sup> Horvath2,<sup>24</sup> and Hannum;<sup>31</sup> two second-generation clocks (*i.e.*, trained to  
116 predict aging-related phenotypes, mortality, and morbidity risk): PhenoAge<sup>25</sup> and GrimAge2;<sup>26</sup> a third-  
117 generation clock (*i.e.*, trained to measure the rate of change of epigenetic age): Dunedin Pace-of-Aging  
118 (DunedinPoAm);<sup>28</sup> and telomere length (DNAmTL).<sup>32</sup> GrimAge2 is an updated version of the GrimAge  
119 biomarker of mortality risk, which includes training on additional DNA methylation-based estimates of  
120 plasma proteins (high sensitivity C-reactive protein (CRP) and hemoglobin A1C). Due to the high  
121 correlation between GrimAge and GrimAge2 in NHANES ( $r = 0.99$ ), we chose to only analyze  
122 GrimAge2. In addition to GrimAge2 calculations, available NHANES data also includes DNA  
123 methylation-based estimates of plasma proteins used in the calculation of this clock.

### 124 *Nutritional biochemistries*

125 Methods for nutritional biochemistries are described on the NHANES website with the respective  
126 data releases.<sup>38,39</sup> Briefly, serum folate and B12 concentrations were measured using the Quantaphase II  
127 Folate/vitamin B12 radioassay kit (Bio-Rad Laboratories, Hercules, CA, US).<sup>38</sup> RBC folate was measured  
128 by diluting samples in ascorbic acid in water and incubating or freezing to hemolyze RBCs. Samples were  
129 diluted again in protein diluent and RBC folate was measured using methods analogous to serum folate.  
130 Plasma Hcy was measured using the Abbott Homocysteine assay, a fluorescence polarization

131 immunoassay, and the Abbott IMX analyzer (Abbott Diagnostics, Chicago, IL, US). MMA was extracted  
132 from plasma or serum with a strong anion exchange resin, and concentrations were measured by gas  
133 chromatography and a mass selective detector.

#### 134 *Covariates*

135 Demographic, socioeconomic, anthropometric measures, and self-reports of health-related  
136 behaviors were collected as part of the NHANES questionnaire and physical examination. As defined by  
137 NHANES, chronological age at the time of the screening interview was calculated from reported date of  
138 birth. In the case of missing date of birth, reported age in years was used to impute date of birth. Self-  
139 reported race and ethnicity were classified as Non-Hispanic White, Mexican American, other Hispanic,  
140 Non-Hispanic Black, or other race including Multiracial. Smoking status was based on the Smoking and  
141 Tobacco Use Questionnaire Section and classified as never (not having smoked at least 100 cigarettes in  
142 life), former (having smoked at least 100 cigarettes in life but not currently smoking), or current (having  
143 smoked at least 100 cigarettes in life and currently smoking every day or some days). Alcohol intake in  
144 average number of drinks per day in the last 12 months was calculated from the Alcohol Use  
145 Questionnaire Section. Occupational status was obtained from the Occupation Questionnaire Section and  
146 classified as white-collar and professional work, white-collar and semi-routine work, blue-collar and  
147 high-skill work, blue-collar and semi-routine work, or no work as described.<sup>40</sup> Education level was  
148 classified as less than high school, high school diploma (including GED), or more than high school. The  
149 poverty to family income ratio (PIR) was based on the Department of Health and Human Services' (HHS)  
150 poverty guidelines and calculated as the family income divided by the poverty guidelines for family size  
151 and year. Body mass index (BMI) in  $\text{kg/m}^2$  was calculated from height and weight measurements  
152 collected by trained technicians during examinations.

153 Data on selected protein concentrations measured in blood were also available in NHANES.  
154 Serum  $\beta$ -2 microglobulin (B2M) concentrations were measured with a B2M immunoassay and serum  
155 cystatin C concentrations were measured with a Cystatin C immunoassay on an automated multi-channel  
156 analyzer (Siemens Healthcare Diagnostics, Tarrytown, NY, US).<sup>41</sup> CRP concentrations were measured



157 using latex-enhanced nephelometry.<sup>42,43</sup> Glycohemoglobin (hemoglobin A1C) concentrations in plasma  
158 were measured using an HPLC-based automated glycohemoglobin analyzer (Primus, Kansas City, MO,  
159 US).<sup>44,45</sup>

#### 160 *Statistical analyses*

161 Among 2,532 participants with epigenetic age estimates, we excluded those with a recorded age  
162 of  $\geq 85$  years ( $n = 130$ ) or with a mismatch between recorded sex and a DNA methylation-based sex  
163 estimate ( $n = 56$ ) (**Supplementary Figure 1**). We calculated epigenetic age deviation (EAD), also known  
164 as epigenetic age acceleration,<sup>46</sup> as the residuals of regressing chronological age in years on epigenetic  
165 age. DunedinPoAm was analyzed centered and scaled. Blood cell type proportions (CB8+ T cells, CD4+  
166 T cells, neutrophils, monocytes, B cells, and natural killer cells) were estimated using regression  
167 calibration<sup>47</sup> based on IDOL probe selection.<sup>48,49</sup>

168 Descriptive statistics before survey weighting were calculated as means and standard deviations  
169 (SDs) for continuous variables and frequencies and proportions for categorical variables. We evaluated  
170 performance of the epigenetic aging biomarkers by calculating correlations and median absolute errors  
171 (MAEs) between chronological age and estimated epigenetic age. Survey weights were provided with the  
172 NHANES epigenetic biomarkers dataset.<sup>35</sup> The survey design was specified using the *Survey* R package  
173 for statistical analyses.<sup>50,51</sup> To preserve the study design, the survey design was specified prior to dropping  
174 participants  $\geq 85$  years old and sex mismatches. Correlations between OCM-related micronutrient  
175 concentrations (serum folate, RBC folate, B12, Hcy, and MMA) were calculated using the *svycor*  
176 function using the bootstrap procedure in the *jtools* R package.<sup>52</sup>

177 We evaluated associations of OCM-related micronutrients and biomarkers with epigenetic aging  
178 biomarkers (EAD residuals or DunedinPoAm) using survey-design weighted generalized linear regression  
179 models. Analyses were conducted using the *svyglm* function in the *Survey* R package.<sup>50,51</sup> The  
180 concentrations of serum folate, RBC folate, B12, Hcy, and methylmalonic acid were  $\log_2$  transformed to  
181 reduce the influence of outliers and meet model assumptions. Primary models were adjusted for potential

182 confounders and precision variables identified *a priori*: chronological age, chronological age<sup>2</sup>, sex, race  
183 and ethnicity, smoking status, education level, occupation, and PIR.

184 Smoking and alcohol intake may be associated with concentrations of OCM-related compounds  
185 due to lifestyle and dietary factors. In addition, smoking<sup>53</sup> and alcohol<sup>54</sup> may act as folate antagonists by  
186 affecting the absorption, metabolism, and maintenance of circulating levels. In our NHANES study  
187 sample, we found that current smoking status compared to never smoking was negatively associated with  
188 the concentrations of serum folate, RBC folate, and MMA and positively associated with the  
189 concentration of Hcy ( $p < 0.05$ ; **Supplemental Tables 1 and 2**), consistent with previous studies.<sup>55,56,56</sup>  
190 Alcohol intake was negatively associated with B12 concentration and positively associated with Hcy  
191 concentration ( $p < 0.05$ ). In addition, former and current smokers reported greater alcohol intake  
192 (drinks/day, never smokers = 0.2; former smokers = 0.4; current smokers = 0.8;  $p < 0.001$ )  
193 (**Supplemental Table 1**). Therefore, we also conducted analyses adjusting for smoking status (former or  
194 current smoking vs. never) and alcohol intake to evaluate if associations of OCM-related compounds and  
195 epigenetic aging biomarkers were independent of these exposures. When adjusting for smoking or alcohol  
196 alone, we saw the largest change in effect sizes with inclusion of smoking in the model (data not shown),  
197 and, consequently, we also tested for interactions between the concentrations of OCM-related compounds  
198 and smoking status by conducting stratified analyses and including an interaction term in unstratified  
199 analyses.

200 We further added log<sub>2</sub>-transformed cystatin C concentration, an indicator of renal function, as a  
201 covariate to the models. Elevated homocysteine can impair renal function, and, in turn, impaired renal  
202 function increases the risk of cardiovascular disease.<sup>57</sup> In addition, poor renal function has been associated  
203 with increased serum folate and RBC folate concentration in a previous study in NHANES.<sup>58</sup>

204 Considering conflicting evidence of the relationship between excess folate and B12 and adverse  
205 health outcomes, including cancer progression and cognition,<sup>59-63</sup> we tested for non-linear associations  
206 using fully adjusted models with folate tertiles (serum folate:  $< 11.2$ ,  $\geq 11.2$  and  $< 17.6$ , and  $\geq 17.6$   
207 ng/mL; RBC folate:  $< 250$ ,  $\geq 250$  and  $< 352$ , and  $\geq 352$  ng/mL RBC) and B12 tertiles ( $< 398$ ,  $\geq 398$  and  $<$

208 583, and  $\geq 583$  pg/mL). We also conducted analyses with the dichotomous variable

209 hyperhomocysteinemia (Hcy concentration  $> 15$   $\mu\text{mol/L}$ )<sup>64</sup> vs. not.

210 To evaluate if individual GrimAge2 components were contributing to the associations with  
211 GrimAge2 EAD, we conducted adjusted analyses of serum folate, RBC folate, and homocysteine  
212 concentrations using GrimAge2 components (plasma protein surrogates and smoking pack years) as the  
213 outcomes. We conducted complementary analyses for proteins with laboratory measures, if available  
214 (B2M, cystatin C, CRP, and hemoglobin A1C).

215 We performed sensitivity analyses adjusting for cell type proportions to distinguish between  
216 intrinsic aging (*i.e.*, intracellular) and extrinsic aging (*i.e.*, reflecting age-related changes in cell type  
217 proportions). Our primary analyses were conducted using complete cases. We also conducted sensitivity  
218 analyses following imputation of missing covariate data. Data were imputed with multiple imputation by  
219 chained equations using the *MICE* R package<sup>65</sup> and 5 iterations. Following imputation, we reanalyzed  
220 associations of OCM-related micronutrients and compounds with aging biomarkers using fully adjusted  
221 weighted generalized linear regression models and pooled estimates from each imputed dataset with the  
222 *pool* function.

223 We used 95% confidence intervals (95% CIs) to evaluate precision of associations and  $p < 0.05$  to  
224 test for statistical significance. All analyses were conducted in R version 4.4.1.<sup>66</sup> We used the STROBE-  
225 nut checklist when writing our report.<sup>67</sup>

226

## 227 **Results**

228 Epigenetic aging biomarker and nutritional biomarker data were available for 2,346 participants.  
229 Participant demographic characteristics and concentrations of OCM-related nutrients and compounds,  
230 prior to survey weighting, are shown in **Table 1**. Participants had a mean (SD) chronological age of 65.1  
231 (9.3) years, and approximately half (51.2%) of participants were male. Nearly all participants were folate  
232 replete; 5 participants had serum folate concentrations less than or equal to the reference value of 3  
233 ng/mL.<sup>68</sup> Twenty-one (0.9%) participants were classified as B12 deficient (concentration  $<150$  pg/mL)

234 and 329 (14.0%) were classified as B12 insufficient (concentration < 300 pg/mL).<sup>8</sup>

235 Hyperhomocysteinemia was more common, with 192 (8.2%) participants having Hcy concentration > 15  
236 umol/L.<sup>64</sup>

237 Participant characteristics stratified by smoking status are shown in **Supplemental Table 1**.

238 Compared to never smokers, former smokers were more likely to be male and had greater alcohol intake,  
239 lower median B12 concentration, and greater median Hcy concentration; current smokers were more  
240 likely to be male and younger, and had lower BMI, greater alcohol intake, lower median concentration of  
241 serum folate and RBC folate, and higher median concentration of Hcy.

242 All first- and second-generation clocks were strongly correlated with chronological age, with  
243 Pearson correlation coefficients ranging from  $r = 0.76$  for PhenoAge to  $r = 0.87$  for Horvath2 ( $p < 0.001$ )  
244 (**Supplemental Figure 2**). The Horvath2 clock had the lowest MAE compared to chronological age (2.71  
245 years) whereas PhenoAge had the largest MAE (10.33 years). As expected, DunedinPoAm was very  
246 weakly correlated with chronological age ( $r = 0.04$ ;  $p = 0.049$ ) and DNAmTL was negatively correlated  
247 with chronological age ( $r = -0.58$ ;  $p < 0.001$ ).

248 After survey weighting, there were moderate correlations of serum folate with RBC folate and  
249 Hcy with MMA ( $r = 0.51$  and  $0.50$ , respectively;  $p < 0.001$ ) (**Supplemental Figure 3**). Serum folate was  
250 significantly but weakly associated with B12 ( $r = 0.04$ ;  $p = 0.034$ ), Hcy ( $r = -0.07$ ;  $p = 0.002$ ), and MMA  
251 ( $r = 0.05$ ;  $p = 0.014$ ). There were also weak correlations of RBC folate with Hcy ( $r = -0.09$ ;  $p < 0.001$ )  
252 and B12 with Hcy ( $r = -0.05$ ;  $p < 0.001$ ) and MMA ( $r = -0.02$ ;  $p < 0.001$ ).

253 *Associations of folate and B12 with epigenetic aging biomarkers*

254 **Figure 2** and **Supplementary Table 3** show results of our analyses of promoters of OCM (*i.e.*,  
255 serum and RBC folate and B12). Our primary analyses used weighted generalized linear regression  
256 models adjusted for chronological age, chronological age<sup>2</sup>, sex, race and ethnicity, BMI, education level,  
257 occupation, and PIR. We additionally adjusted for self-reported smoking status, alcohol intake, and  
258 cystatin C, an indicator of renal function.

259 Each doubling of serum folate concentration was associated with -0.82 years (95% CI = -1.40, -  
260 0.23;  $p = 0.010$ ) lower GrimAge EAD, -0.13 SDs (95% CI = -0.22, -0.03;  $p = 0.015$ ) lower  
261 DunedinPoAm, and 0.02 kb (95% CI = 0.00, 0.04;  $p = 0.037$ ) greater DNAmTL EAD. After adjusting for  
262 smoking status and alcohol intake, serum folate concentration modeled continuously was not significantly  
263 associated with any epigenetic aging biomarker ( $p > 0.05$ ); however, the third vs. first tertile of serum  
264 folate was positively associated with DNAmTL EAD ( $B$  (95% CI) = 0.04 kb (0.01, 0.07);  $p = 0.043$ )  
265 (**Supplemental Table 4**). After adjusting for cystatin C, serum folate was associated with GrimAge2  
266 EAD ( $B$  (95% CI) = -0.46 years per doubling (-0.91, -0.01);  $p = 0.047$ ), but not DunedinPoAm or  
267 DNAmTL EAD. In analyses stratified by smoking status, serum folate concentration was negatively  
268 associated with GrimAge2 EAD ( $B$  (95% CI) = -1.42 years per doubling (-2.50, -0.34);  $p = 0.014$ ) and  
269 DunedinPoAm ( $B$  (95% CI) = -0.24 SDs (-0.45, -0.03);  $p = 0.031$ ) among current smokers (*i.e.*, the group  
270 with significantly lower serum folate concentration), but not among never or former smokers, although  
271 the serum folate and smoking interaction term was not significant (**Supplemental Table 5**).

272 Before controlling for smoking status and alcohol intake, RBC folate concentration was  
273 positively associated with PhenoAge EAD ( $B = 0.88$  years per doubling; 95% CI = -0.10, 1.85;  $p = 0.07$ ),  
274 although this association did not reach statistical significance (**Figure 2** and **Supplementary Table 3**).  
275 With adjustment for smoking and alcohol, the association of RBC folate concentration and PhenoAge  
276 EAD increased ( $B = 1.06$  years per doubling; 95% CI = -0.03, 2.14;  $p = 0.06$ ), and there was a trend  
277 toward a positive association with GrimAge2 EAD ( $B = 0.59$  years per doubling; 95% CI = -0.08, 1.26;  $p$   
278 = 0.08), and DunedinPoAm ( $B = 0.11$  SDs per doubling; 95% CI = -0.08, 1.26;  $p = 0.08$ ). RBC folate  
279 concentration among former smokers were not significantly different from those of never smokers.  
280 However, among former smokers, RBC folate concentration was significantly associated with GrimAge2  
281 EAD ( $B = 1.15$  years per doubling; 95% CI = 0.40, 1.89;  $p = 0.006$ ) and DunedinPoAm ( $B = 0.15$  SDs per  
282 doubling; 95% CI = 0.00, 0.30;  $p = 0.047$ ) (**Supplemental Table 5**). Associations were not significant  
283 among never or current smokers; however, the interaction term was not significant.

284 B12 concentration and tertiles were not significantly associated with any epigenetic aging  
285 biomarker ( $p > 0.05$ ).

### 286 *Associations of homocysteine and methylmalonic acid with epigenetic aging biomarkers*

287 Associations of markers of OCM deficiencies (*i.e.*, Hcy and MMA) with epigenetic aging  
288 biomarkers are shown in **Figure 3** and **Supplementary Table 3**. Hcy concentration was positively  
289 associated with PhenoAge EAD ( $B$  (95% CI) = 1.05 years per doubling (0.06, 2.04);  $p = 0.039$ ),  
290 GrimAge2 EAD ( $B$  (95% CI) = 1.93 years per doubling (1.16, 2.71);  $p < 0.001$ ), and DunedinPoAm ( $B$   
291 (95% CI) = 0.26 SDs per doubling (0.10, 0.41);  $p = 0.003$ ). After adjusting for smoking status and alcohol  
292 intake, associations of Hcy with GrimAge2 EAD and DunedinPoAm remained significant but attenuated  
293 (GrimAge2 EAD:  $B$  (95% CI) = 1.32 years per doubling (0.69, 1.94);  $p = 0.001$  and DunedinPoAm:  $B$   
294 (95% CI) = 0.14 SDs per doubling (0.00, 0.27);  $p = 0.048$ ). With cystatin C adjustment, the association  
295 with GrimAge2 EAD was further attenuated ( $B$  (95% CI) = 0.82 years per doubling (0.05, 1.60);  $p =$   
296 0.040), and the association with DunedinPoAm was null. Hyperhomocysteinemia vs. normal Hcy range  
297 was associated with greater PhenoAge EAD ( $B$  (95% CI) = 1.97 years (0.54, 3.40);  $p = 0.012$ ) and  
298 GrimAge2 EAD ( $B$  (95% CI) = 2.00 years (0.83, 3.17);  $p = 0.003$ ) (**Supplemental Table 4**). In stratified  
299 analyses, Hcy concentration was significantly and positively associated with GrimAge2 EAD among  
300 former smokers ( $B$  (95% CI) = 1.47 years year doubling (0.47, 2.48);  $p = 0.008$ ) and current smokers ( $B$   
301 (95% CI) = 1.76 years per doubling (0.50, 3.03);  $p = 0.010$ ), but not among never smokers ( $B$  (95% CI) =  
302 0.82 years per doubling (-0.11, 1.75);  $p = 0.08$ ), with significant interaction between Hcy concentration  
303 and former vs. never smoking ( $p_{int} = 0.027$ ) (**Figure 4** and **Supplemental Table 5**).

304 MMA concentration was not associated with the epigenetic aging biomarkers in our primary  
305 analyses. However, among former smokers, MMA was positively associated with PhenoAge EAD ( $B$   
306 (95% CI) = 0.88 years per doubling (0.16, 1.60);  $p = 0.021$ ).

### 307 *Associations with GrimAge2 components*

308 GrimAge2 is calculated as a weighted linear combination of DNA methylation-based surrogates  
309 for 9 plasma proteins and smoking pack years. Therefore, to evaluate if individual components of

310 GrimAge2 were driving the associations of serum folate, RBC folate, and Hcy with GrimAge2 EAD, we  
311 evaluated associations of each of the components separately. For serum folate concentration, only the  
312 association with the surrogate for smoking pack years was significant, even after adjusting for self-  
313 reported smoking status (Z-score scale) ( $B$  (95% CI) = -0.07 per doubling (-0.13, -0.01);  $p = 0.033$ )  
314 (**Table 2**). RBC folate concentration was significantly associated with GDF15 ( $B$  (95% CI) = 0.07 per  
315 doubling (0.01, 0.03);  $p = 0.023$ ), PAI1 ( $B$  (95% CI) = 0.14 per doubling (0.01, 0.27);  $p = 0.038$ ), and  
316 log(CRP) ( $B$  (95% CI) = 0.23 per doubling (0.11, 0.35);  $p = 0.002$ ). Hcy concentration was positively  
317 associated with five GrimAge2 components: B2M ( $B$  (95% CI) = 0.14 per doubling (0.06, 0.22);  $p =$   
318 0.002), Cystatin C ( $B$  (95% CI) = 0.09 per doubling (0.02, 0.16);  $p = 0.021$ ), TIMP1 ( $B$  (95% CI) = 0.08  
319 per doubling (0.03, 0.13);  $p = 0.005$ ), ADM ( $B$  (95% CI) = 0.17 per doubling (0.06, 0.29);  $p = 0.007$ ), and  
320 smoking pack years ( $B$  (95% CI) = 0.15 per doubling (0.02, 0.28);  $p = 0.030$ ).

321 Laboratory measures for serum B2M and cystatin C concentrations, CRP concentration, and  
322 hemoglobin A1C were also available in these NHANES cycles. Within our sample, all GrimAge2  
323 components were moderately correlated with their measured counterparts (without survey weighting:  
324 B2M:  $r = 0.25$ ; cystatin C:  $r = 0.22$ ; CRP:  $r = 0.28$ ; hemoglobin A1C:  $r = 0.50$ ;  $p < 0.001$ ). Therefore, we  
325 also tested if Hcy concentration was significantly associated with measured values (**Table 2**). Overall,  
326 results were consistent with those of the GrimAge2 components. However, RBC folate concentration was  
327 positively associated  $\log_2$ (cystatin C) ( $B$  (95% CI) = 0.11 per doubling (0.01, 0.21);  $p = 0.029$ )  
328 Hcy concentration was also associated with lower  $\log_2$ (hemoglobin A1C) ( $B$  (95% CI) = -0.04 per  
329 doubling (0.06, 0.02)).

### 330 *Sensitivity analyses*

331 In sensitivity analyses adjusting for estimated cell type proportions, results were similar to those  
332 of our primary analyses but attenuated (**Supplemental Table 6**). The association of Hcy concentration  
333 with GrimAge2 EAD remained significant ( $B$  (95% CI) = 1.13 years per doubling (0.52, 1.75);  $p =$   
334 0.007). Analyses using imputed covariate data were also largely consistent with our primary analyses  
335 (**Supplemental Table 7**). A doubling in Hcy concentration was associated with 1-year greater PhenoAge

336 EAD (95% CI = 0.13, 1.87,  $p = 0.029$ ), 1.44 years greater GrimAge2 EAD (95% CI = 0.87, 2.00,  $p$   
337 <0.001), and 0.17 SD greater DunedinPoAm (95% CI = 0.04, 0.31,  $p = 0.019$ ).

338

### 339 **Discussion**

340 We tested associations of OCM-related biomarkers with epigenetic aging biomarkers in  
341 NHANES, a nationally representative sample of adults in the US where DNA methylation was assayed on  
342 the population age 50 and older. The strongest and most robust associations were with EAD measured by  
343 second generation clocks. We provide evidence that greater concentration of Hcy, an indicator of OCM  
344 deficiencies, is associated with greater GrimAge2 EAD and DunedinPoAm. For each doubling of Hcy  
345 concentration, GrimAge2 EAA was 1.32 years greater and DunedinPoAm was 0.14 SDs greater. This  
346 association persisted after adjustment for smoking status and alcohol intake – folate antagonists and  
347 behaviors associated with poor diet quality. We also found that serum folate concentration was  
348 significantly associated with lower GrimAge2 EAD and DunedinPoAm and greater DNAmTL EAD;  
349 however, associations were imprecise after adjusting for smoking status and alcohol intake. Similarly, the  
350 association of Hcy concentration with greater PhenoAge EAD was attenuated after controlling for  
351 smoking and alcohol. It is known that smoking and alcohol intake are associated with increased EAD,<sup>69–71</sup>  
352 and changes in OCM-related biomarkers may be one mechanism through which this occurs.

353 While our study did not directly investigate clinical endpoints, our findings support previous  
354 research linking elevated Hcy to adverse age-related health outcomes, including cognitive impairment and  
355 decline,<sup>18</sup> cardiovascular disease incidence and<sup>17</sup> mortality<sup>17</sup> and all-cause mortality.<sup>17</sup> Particularly  
356 relevant to the current study, in NHANES 1999–2006, Hcy has been associated with increased all-cause  
357 mortality and CVD mortality.<sup>72</sup> GrimAge2 is an epigenetic clock developed to estimate mortality risk.<sup>26</sup>  
358 GrimAge2 is calculated as the weighted linear combination of sex, age, and DNA methylation surrogates  
359 for smoking pack years and 9 plasma proteins (adrenomedullin (ADM), B2M, cystatin C, growth  
360 differentiation factor 15 (GDF-15), leptin, CRP, hemoglobin A1C, plasminogen activation inhibitor 1  
361 (PAI-1), and tissue inhibitor metalloproteinase 1 (TIMP-1)). In addition to the overall positive association



362 of Hcy concentration and hyperhomocysteinemia with GrimAge2 EAD, we found that Hcy was  
363 associated with greater DNA methylation surrogates of B2M (a biomarker of cardiovascular disease,  
364 kidney function, and inflammation<sup>73</sup>), cystatin C (a biomarker of kidney function<sup>74</sup>), TIMP1 (a regulator  
365 of cell growth<sup>75</sup> and inflammation<sup>76</sup>), ADM (a vasodilator and prognostic marker in CVD<sup>77</sup>), and smoking  
366 pack years. In addition, analyses of directly measured protein levels were consistent with our findings on  
367 epigenetic estimates. In stratified analyses, we found evidence that Hcy has a stronger association with  
368 GrimAge2 EAD among former and current smokers compared to never smokers.

369 DunedinPoAm is an epigenetic biomarker that estimates the rate of change of 18 biomarkers  
370 capturing organ-system integrity and was trained on data over a 12-year span.<sup>28</sup> The biomarkers included  
371 both blood biochemistries (*e.g.*, hemoglobin A1C, CRP, lipoprotein (a), HDL cholesterol) and functional  
372 and cardiometabolic measurements (*e.g.*, BMI, cardiorespiratory fitness, pulmonary function). Greater  
373 DunedinPoAm has been associated with greater physical and cognitive decline, morbidity, and  
374 mortality.<sup>28</sup> In our study, Hcy was positively associated with DunedinPoAm and was robust to smoking  
375 and alcohol adjustment. However, this association was null after adjustment for cystatin C, suggesting  
376 that kidney function may be involved in the mechanism linking Hcy to DunedinPoAm.

377 We also found significant negative associations of serum folate with GrimAge2 EAD and  
378 DunedinPoAm before adjusting for smoking and alcohol. After smoking and alcohol intake adjustment,  
379 associations remained negative but did not reach statistical significance. Stratified analyses suggested that  
380 folate may be protective against increased DunedinPoAm and GrimAge2 EAD among smokers, although  
381 we did not find significant Hcy and smoking interaction. However, our analyses of smoking-specific  
382 effects are limited by small sample size ( $N = 811$  never smokers,  $N = 732$  former smokers, and  $N = 287$   
383 current smokers with complete serum folate and complete covariate data).

384 In contrast to our hypothesis that higher folate concentration would be protective against  
385 epigenetic aging, we observed a trend toward a positive association between RBC folate concentration  
386 and epigenetic aging measured by second generation clocks and DunedinPoAm. Although these  
387 associations did not reach statistical significance in the NHANES sample overall, associations of RBC

388 folate with GrimAge2 EAD and DunedinPoAm were positive and significant among former smokers.  
389 Serum folate and RBC folate are both indicators of folate deficiency and were significantly correlated in  
390 our study. Although RBC folate is reflective of long-term folate status, measurement of RBC folate is  
391 more costly, has greater analytical variability, and has not shown diagnostic value in clinical settings  
392 beyond that of serum folate concentrations.<sup>78</sup> We hypothesize that RBC folate concentration may also  
393 capture pathophysiological changes beyond serum folate measurements. Red blood cell abnormalities,  
394 including megaloblastic anemia, macrocytosis, and increased mean cell volume and red cell distribution  
395 width, are associated with folate and B12 deficiencies.<sup>79</sup> However, cell distribution width has also been  
396 positively associated with inflammatory markers and oxidative stress,<sup>80,81</sup> and RBCs may be involved in  
397 inflammatory processes due to their cytokine binding capacity.<sup>82</sup> The second generation clocks and  
398 DunedinPoAm are trained on biomarkers of inflammation, such as CRP (PhenoAge, GrimAge2,  
399 DunedinPoAm), white blood cell count (DunedinPoAm), mean cell volume (PhenoAge), and red blood  
400 cell distribution width (PhenoAge), and therefore these clocks may be sensitive to inflammatory-related  
401 variations in RBCs. Furthermore, RBC folate concentration was positively associated with cystatin C,  
402 both in our study and a previous analysis of NHANES.<sup>58</sup> The relationship between RBC folate and the  
403 second-generation clocks may also be reflecting impaired renal function related in aging and chronic  
404 disease development. These explanations are supported by our analyses of RBC folate concentration with  
405 the GrimAge2 components and measured proteins related to inflammation and renal function.

406         Associations of plasma folate, B12, B6, and Hcy with Horvath1 EAD, PhenoAge EAD, and  
407 GrimAge EAD have previously been investigated in the Veterans Affairs Normative Aging Study, a  
408 cohort of older community-dwelling men ( $N = 715$ ).<sup>83</sup> This study used Bayesian Kernel Machine  
409 Regression (BKMR), a mixture approach that allows for the selection of statistically important  
410 independent variables. B6 was identified as important for predicting PhenoAge EAD with a negative  
411 direction of association, and folate was identified as important for predicting GrimAge EAD and  
412 PhenoAge EAD with positive directions of associations. Our findings were not consistent with these  
413 results, possibly due to differences in populations studied and analytical differences. BKMR produces

414 single-exposure effect estimates holding all other exposures at a fixed percentile. Given the complex  
415 relationship between nutritional factors and OCM metabolites, including an antagonistic relationship  
416 between one-carbon donors and Hcy, it may be difficult to interpret effects of folate when B12, B6, and  
417 Hcy are evaluated at a common percentile.

418       Associations of OCM-related compounds and epigenetic aging have also been analyzed in a  
419 supplementation study among older adults with mild cognitive impairment ( $N = 217$ ). This study reported  
420 a positive correlation between baseline plasma Hcy and rate of aging (*i.e.*, epigenetic age divided by  
421 chronological age) measured by Horvath<sup>2</sup>, Hannum, Zhang,<sup>84</sup> DunedinPACE,<sup>85</sup> and Index, a  
422 commercially available epigenetic clock (Elysium Health, New York, NY, US).<sup>86</sup> Furthermore, this study  
423 found evidence that supplementation with a B-vitamin complex (B6, B12, and folic acid) may decrease  
424 epigenetic age among individuals with hyperhomocysteinemia.

425       Understanding the relationship between OCM-related compounds and epigenetic aging  
426 biomarkers may help advance the study of nutrition and aging. Randomized controlled trials have  
427 demonstrated that folic acid supplementation lowers homocysteine levels,<sup>87,88</sup> particularly among  
428 individuals with low baseline folate.<sup>89</sup> However, there is less evidence for the downstream health benefits  
429 of supplementation with folic acid or other B vitamins. In a 7-year study of women with high risk of CVD  
430 ( $N = 5,442$ ), supplementation with folic acid, B6, and B12 did not significantly reduce the risk of  
431 cardiovascular events compared to placebo, despite a significant reduction in homocysteine levels in the  
432 treatment group.<sup>90</sup> Similarly, a 3-year study of adults with cerebral infarction ( $N = 3,680$ ) found no  
433 association of supplementation with folic acid, B6, and B12 with risk of stroke, although lower Hcy was  
434 associated with reduced risk of coronary heart disease events.<sup>91</sup> Meta-analyses of folic acid trials  
435 concluded that supplementation may reduce the risk of stroke but not mortality<sup>92</sup>, and that reductions in  
436 CVD were greatest among individuals with low baseline folate and high reductions in Hcy.<sup>93</sup> Inconsistent  
437 results have been found for studies of folic acid and B vitamin supplementation and cognitive  
438 function;<sup>94,95</sup> effects may also be modified by baseline nutritional status.<sup>96</sup> Variation in results of clinical  
439 trials may be due in part to differences in outcomes measured and follow-up time. Although these studies

440 focused on clinical outcomes, future research may leverage epigenetic aging biomarkers as surrogate  
441 endpoints in clinical trials that represent intermediate changes in complex biological pathways.<sup>97</sup> Our  
442 results support the use of some of these biomarkers to test and monitor intervention prior to disease  
443 diagnosis or onset.

444 Our study was strengthened by its large sample size and population representative of middle-aged  
445 and older adults in the US. We were able to analyze associations with multiple OCM-related compounds  
446 and epigenetic clocks to better understand nuances in the relationships between OCM and aging-related  
447 biomarkers. However, we were limited by cross-sectional data and the inability to evaluate the effects of  
448 changes in OCM status on long-term epigenetic aging and health. A portion of our sample had missing  
449 data on covariates and therefore our primary analyses were restricted to complete cases; however,  
450 sensitivity analyses using imputed data were consistent. Additionally, we were limited by the nutritional  
451 biomarker data available for NHANES. A more comprehensive study including additional OCM-related  
452 micronutrients (*e.g.*, choline, betaine and B6) may provide further insights to the relationship between  
453 nutrition and epigenetic aging. Our study was also unable to analyze effect modification by genetic  
454 factors that affect OCM, such as variants in methylenetetrahydrofolate reductase (*MTHFR*), the enzyme  
455 that processes folate. Multiple testing was not conducted, and therefore some findings might be due to  
456 chance. However, we focused on precision of estimates along with pre-hypothesized associations, making  
457 such adjustments non-essential. Furthermore, our study was limited to a sample representative of the US  
458 adult population, and therefore findings may not be generalizable to populations with different dietary  
459 habits, nutritional status, lifestyle habits, and ages.

460

## 461 **Conclusion**

462 As the application of epigenetic aging biomarkers becomes more common in research and clinical  
463 settings, it is important to understand how intervenable factors, such as nutrition, influence epigenetic  
464 aging. In this study of a nationally representative sample of middle-aged and older adults, we found that  
465 Hcy concentration is positively associated with epigenetic aging measured by GrimAge2 and

466 DunedinPoAm, particularly among former and current smokers. We also provide evidence that serum  
467 folate is associated with lower GrimAge2 EAD and DunedinPoAm and higher DNAmTL EAD. These  
468 associations were attenuated after adjusting for smoking status and alcohol intake, suggesting that  
469 changes in OCM-related biomarkers may be one mechanism through behavioral factors are related to  
470 EAD. Future studies should address the long-term health consequences of OCM-related epigenetic aging  
471 and investigate associations in subpopulations such as smokers that may have greater benefit from  
472 nutritional interventions.

473

474 **Conflicts of interest:** The authors have no conflicts of interest to disclose.

475

476 **Declaration of generative AI in scientific writing:** No writing AI assistance was utilized in the writing  
477 or production of this manuscript.

478

479 **Data sharing:** All datasets analyzed in the current study are publicly available from the NHANES  
480 website.

481 **References**

- 482
- 483 1. Lionaki E, Ploumi C, Tavernarakis N. One-carbon metabolism: pulling the strings behind  
484 aging and neurodegeneration. *Cells* 2022; 11:214.
- 485 2. Paul L, Selhub J. Interaction between excess folate and low vitamin B12 status. *Molecular*  
486 *Aspects of Medicine* 2017; 53:43–7.
- 487 3. Ducker GS, Rabinowitz JD. One-carbon metabolism in health and disease. *Cell Metab*  
488 2017; 25:27–42.
- 489 4. Scott JM, Weir DG. Folic acid, homocysteine and one-carbon metabolism: a review of the  
490 essential biochemistry. *J Cardiovasc Risk* 1998; 5:223–7.
- 491 5. Bozack AK, Saxena R, Gamble MV. Nutritional influences on one-carbon metabolism:  
492 Effects on arsenic methylation and toxicity. *Annu Rev Nutr* 2018; 38:401–29.
- 493 6. Tejero J, Lazure F, Gomes A. Methylmalonic acid in aging and disease. *Trends Endocrinol*  
494 *Metab* 2024; 35:188–200.
- 495 7. Office of Dietary Supplements - Folate [Internet]. [cited 2024 Dec 2]; Available from:  
496 <https://ods.od.nih.gov/factsheets/Folate-HealthProfessional/>
- 497 8. Office of Dietary Supplements - Vitamin B12 [Internet]. [cited 2024 Dec 2]; Available  
498 from: <https://ods.od.nih.gov/factsheets/VitaminB12-HealthProfessional/>
- 499 9. Araújo JR, Martel F, Borges N, Araújo JM, Keating E. Folates and aging: role in mild  
500 cognitive impairment, dementia and depression. *Ageing Research Reviews* 2015; 22:9–19.
- 501 10. Clarke R, Grimley Evans J, Schneede J, Nexo E, Bates C, Fletcher A, Prentice A, Johnston  
502 C, Ueland PM, Refsum H, et al. Vitamin B12 and folate deficiency in later life. *Age Ageing*  
503 2004; 33:34–41.
- 504 11. Hazra A, Selhub J, Chao W-H, Ueland P, Hunter, Baron J. Uracil misincorporation into  
505 DNA and folic acid supplementation. *Am J Clin Nutr* 2010; 91:160–5.
- 506 12. Reynolds E. Folic acid, ageing, depression, and dementia. *BMJ* 2002; 324:1512–5.
- 507 13. O'Connor DMA, Scarlett S, De Looze C, O'Halloran AM, Laird E, Molloy AM, Clarke R,  
508 McGarrigle CA, Kenny RA. Low folate predicts accelerated cognitive decline: 8-year  
509 follow-up of 3140 older adults in Ireland. *Eur J Clin Nutr* 2022; 76:950–7.
- 510 14. Bailey LB, Stover PJ, McNulty H, Fenech MF, Gregory JF, Mills JL, Pfeiffer CM, Fazili Z,  
511 Zhang M, Ueland PM, et al. Biomarkers of nutrition for development—folate review. *The*  
512 *Journal of Nutrition* 2015; 145:1636S-1680S.
- 513 15. He H, Shui B. Folate intake and risk of bladder cancer: a meta-analysis of epidemiological  
514 studies. *Int J Food Sci Nutr* 2014; 65:286–92.

- 515 16. Lentz SR. Mechanisms of homocysteine-induced atherothrombosis. *Journal of Thrombosis*  
516 *and Haemostasis* 2005; 3:1646–54.
- 517 17. Humphrey LL, Fu R, Rogers K, Freeman M, Helfand M. Homocysteine level and coronary  
518 heart disease incidence: a systematic review and meta-analysis. *Mayo Clin Proc* 2008;  
519 83:1203–12.
- 520 18. Smith A, Refsum. Homocysteine, B vitamins, and cognitive impairment. *Annu Rev Nutr*  
521 2016; 36:211–39.
- 522 19. Zuliani G, Brombo G, Polastri M, Romagnoli T, Aarons G, Riccetti R, Seripa D, Trentini  
523 A, Cervellati C. High plasma homocysteine levels predict the progression from mild  
524 cognitive impairment to dementia. *Neurochem Int* 2024; 177:105763.
- 525 20. Zhang G, Liu S, Xu Y, Ma L-Y, Zhang W, Ji Y. Elevated plasma total homocysteine levels  
526 are associated with behavioral and psychological symptoms in dementia with Lewy bodies.  
527 *Front Neurosci* 2024; 18:1406694.
- 528 21. Xu Y, Qian X, Zhang M, Liang M. Correlations of cognitive function with serum levels of  
529 homocysteine, sex hormone binding globulin, and leptin in patients with schizophrenia. *Pak*  
530 *J Med Sci* 2024; 40:2319–23.
- 531 22. Unadkat SV, Padhi BK, Bhongir AV, Gandhi AP, Shamim MA, Dahiya N, Satapathy P,  
532 Rustagi S, Khatib MN, Gaidhane A, et al. Association between homocysteine and coronary  
533 artery disease—trend over time and across the regions: a systematic review and meta-  
534 analysis. *The Egyptian Heart Journal* 2024; 76:29.
- 535 23. Horvath S. DNA methylation age of human tissues and cell types. *Genome Biol* 2013;  
536 14:R115.
- 537 24. Horvath S, Oshima J, Martin GM, Lu AT, Quach A, Cohen H, Felton S, Matsuyama M,  
538 Lowe D, Kabacik S, et al. Epigenetic clock for skin and blood cells applied to Hutchinson  
539 Gilford Progeria Syndrome and ex vivo studies. *Aging* 2018; 10:1758–75.
- 540 25. Levine ME, Lu AT, Quach A, Chen BH, Assimes TL, Bandinelli S, Hou L, Baccarelli AA,  
541 Stewart JD, Li Y, et al. An epigenetic biomarker of aging for lifespan and healthspan.  
542 *Aging* 2018; 10:573–91.
- 543 26. Lu AT, Binder AM, Zhang J, Yan Q, Reiner AP, Cox SR, Corley J, Harris SE, Kuo P-L,  
544 Moore AZ, et al. DNA methylation GrimAge version 2. *Aging* 14:9484–549.
- 545 27. Lu AT, Quach A, Wilson JG, Reiner AP, Aviv A, Raj K, Hou L, Baccarelli AA, Li Y,  
546 Stewart JD, et al. DNA methylation GrimAge strongly predicts lifespan and healthspan.  
547 *Aging* 2019; 11:303–27.
- 548 28. Belsky DW, Caspi A, Arseneault L, Baccarelli A, Corcoran DL, Gao X, Hannon E,  
549 Harrington HL, Rasmussen LJ, Houts R, et al. Quantification of the pace of biological

- 550 aging in humans through a blood test, the DunedinPoAm DNA methylation algorithm.  
551 eLife 2020; 9:e54870.
- 552 29. Chen BH, Marioni RE, Colicino E, Peters MJ, Ward-Caviness CK, Tsai P-C, Roetker NS,  
553 Just AC, Demerath EW, Guan W, et al. DNA methylation-based measures of biological  
554 age: meta-analysis predicting time to death. *Aging* 2016; 8:1844–65.
- 555 30. Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of  
556 ageing. *Nat Rev Genet* 2018; 19:371–84.
- 557 31. Hannum G, Guinney J, Zhao L, Zhang L, Hughes G, Sada S, Klotzle B, Bibikova M, Fan  
558 J-B, Gao Y, et al. Genome-wide methylation profiles reveal quantitative views of human  
559 aging rates. *Mol Cell* 2013; 49:359–67.
- 560 32. Lu AT, Seeboth A, Tsai P-C, Sun D, Quach A, Reiner AP, Kooperberg C, Ferrucci L, Hou  
561 L, Baccarelli AA, et al. DNA methylation-based estimator of telomere length. *Aging* 2019;  
562 11:5895–923.
- 563 33. NHANES - About the National Health and Nutrition Examination Survey [Internet]. 2024  
564 [cited 2024 Nov 26]; Available from: [https://www.cdc.gov/nchs/nhanes/about\\_nhanes.htm](https://www.cdc.gov/nchs/nhanes/about_nhanes.htm)
- 565 34. CDC. Ethics Review Board Approval [Internet]. National Health and Nutrition  
566 Examination Survey2024 [cited 2024 Dec 19]; Available from:  
567 <https://www.cdc.gov/nchs/nhanes/about/erb.html>
- 568 35. NHANES 1999-2002 DNA Methylation Array and Epigenetic Biomarkers [Internet]. [cited  
569 2024 Nov 26]; Available from: <https://wwwn.cdc.gov/Nchs/Nhanes/DNA/Default.aspx>
- 570 36. Illumina. Infinium MethylationEPIC BeadChip data sheet. 2015; Available from:  
571 [http://www.illumina.com/content/dam/illumina-](http://www.illumina.com/content/dam/illumina-marketing/documents/products/datasheets/humanmethylationepic-data-sheet-1070-2015-008.pdf)  
572 [marketing/documents/products/datasheets/humanmethylationepic-data-sheet-1070-2015-](http://www.illumina.com/content/dam/illumina-marketing/documents/products/datasheets/humanmethylationepic-data-sheet-1070-2015-008.pdf)  
573 [008.pdf](http://www.illumina.com/content/dam/illumina-marketing/documents/products/datasheets/humanmethylationepic-data-sheet-1070-2015-008.pdf)
- 574 37. Teschendorff AE, Marabita F, Lechner M, Bartlett T, Tegner J, Gomez-Cabrero D, Beck S.  
575 A beta-mixture quantile normalization method for correcting probe design bias in Illumina  
576 Infinium 450 k DNA methylation data. *Bioinformatics* 2013; 29:189–96.
- 577 38. LAB06 [Internet]. [cited 2024 Dec 17]; Available from:  
578 <https://wwwn.cdc.gov/Nchs/Data/Nhanes/Public/1999/DataFiles/LAB06.htm>
- 579 39. L06\_B [Internet]. [cited 2024 Dec 17]; Available from:  
580 [https://wwwn.cdc.gov/Nchs/Data/Nhanes/Public/2001/DataFiles/L06\\_B.htm](https://wwwn.cdc.gov/Nchs/Data/Nhanes/Public/2001/DataFiles/L06_B.htm)
- 581 40. Rehkopf DH, Berkman LF, Coull B, Krieger N. The non-linear risk of mortality by income  
582 level in a healthy population: US National Health and Nutrition Examination Survey  
583 mortality follow-up cohort, 1988-2001. *BMC Public Health* 2008; 8:383.



- 584 41. SSCARD\_A [Internet]. [cited 2024 Dec 19]; Available from:  
585 [https://wwwn.cdc.gov/Nchs/Data/Nhanes/Public/1999/DataFiles/SSCARD\\_A.htm](https://wwwn.cdc.gov/Nchs/Data/Nhanes/Public/1999/DataFiles/SSCARD_A.htm)
- 586 42. LAB11 [Internet]. [cited 2024 Dec 19]; Available from:  
587 <https://wwwn.cdc.gov/Nchs/Data/Nhanes/Public/1999/DataFiles/LAB11.htm>
- 588 43. L11\_B [Internet]. [cited 2024 Dec 19]; Available from:  
589 [https://wwwn.cdc.gov/Nchs/Data/Nhanes/Public/2001/DataFiles/L11\\_B.htm](https://wwwn.cdc.gov/Nchs/Data/Nhanes/Public/2001/DataFiles/L11_B.htm)
- 590 44. LAB10 [Internet]. [cited 2024 Dec 19]; Available from:  
591 <https://wwwn.cdc.gov/Nchs/Data/Nhanes/Public/1999/DataFiles/LAB10.htm>
- 592 45. L10\_B [Internet]. [cited 2024 Dec 19]; Available from:  
593 [https://wwwn.cdc.gov/Nchs/Data/Nhanes/Public/2001/DataFiles/L10\\_B.htm](https://wwwn.cdc.gov/Nchs/Data/Nhanes/Public/2001/DataFiles/L10_B.htm)
- 594 46. Moqri M, Herzog C, Poganik JR, Biomarkers of Aging Consortium, Justice J, Belsky DW,  
595 Higgins-Chen A, Moskalev A, Fuellen G, Cohen AA, et al. Biomarkers of aging for the  
596 identification and evaluation of longevity interventions. *Cell* 2023; 186:3758–75.
- 597 47. Houseman EA, Accomando WP, Koestler DC, Christensen BC, Marsit CJ, Nelson HH,  
598 Wiencke JK, Kelsey KT. DNA methylation arrays as surrogate measures of cell mixture  
599 distribution. *BMC Bioinformatics* 2012; 13:86.
- 600 48. Koestler DC, Jones MJ, Usset J, Christensen BC, Butler RA, Kobor MS, Wiencke JK,  
601 Kelsey KT. Improving cell mixture deconvolution by identifying optimal DNA methylation  
602 libraries (IDOL). *BMC Bioinformatics* 2016; 17:120.
- 603 49. Salas LA, Koestler DC, Butler RA, Hansen HM, Wiencke JK, Kelsey KT, Christensen BC.  
604 An optimized library for reference-based deconvolution of whole-blood biospecimens  
605 assayed using the Illumina HumanMethylationEPIC BeadArray. *Genome Biology* 2018;  
606 19:64.
- 607 50. Lumley T, Gao P, Schneider B. survey: Analysis of Complex Survey Samples [Internet].  
608 2024 [cited 2024 Sep 5]; Available from: [https://cran.r-](https://cran.r-project.org/web/packages/survey/index.html)  
609 [project.org/web/packages/survey/index.html](https://cran.r-project.org/web/packages/survey/index.html)
- 610 51. Lumley T. Analysis of Complex Survey Samples. *Journal of Statistical Software* 2004; 9:1–  
611 19.
- 612 52. Long JA. jtools: analysis and presentation of social scientific data. *Journal of Open Source*  
613 *Software* 2024; 9:6610.
- 614 53. Northrop-Clewes CA, Thurnham DI. Monitoring micronutrients in cigarette smokers.  
615 *Clinica Chimica Acta* 2007; 377:14–38.
- 616 54. Halsted CH, Villanueva JA, Devlin AM, Chandler CJ. Metabolic interactions of alcohol  
617 and folate. *J Nutr* 2002; 132:2367S-2372S.

- 618 55. Okumura K, Tsukamoto H. Folate in smokers. *Clin Chim Acta* 2011; 412:521–6.
- 619 56. Gabriel HE, Crott JW, Ghandour H, Dallal GE, Choi S-W, Keyes MK, Jang H, Liu Z,  
620 Nadeau M, Johnston A, et al. Chronic cigarette smoking is associated with diminished  
621 folate status, altered folate form distribution, and increased genetic damage in the buccal  
622 mucosa of healthy adults. *Am J Clin Nutr* 2006; 83:835–41.
- 623 57. Hirata A. Is renal function the key to disease risk management in elevated homocysteine  
624 levels? *Hypertens Res* 2024; 47:1976–7.
- 625 58. Wang A, Yeung LF, Ríos Burrows N, Rose CE, Fazili Z, Pfeiffer CM, Crider KS. Reduced  
626 Kidney Function Is Associated with Increasing Red Blood Cell Folate Concentration and  
627 Changes in Folate Form Distributions (NHANES 2011–2018). *Nutrients* 2022; 14:1054.
- 628 59. Thabet RH, Alessa REM, Al-Smadi ZKK, Alshatnawi BSG, Amayreh BMI, Al-Dwaaghreh  
629 RBA, Salah SKA. Folic acid: friend or foe in cancer therapy. *J Int Med Res* 2024;  
630 52:03000605231223064.
- 631 60. Morris M, Evans D, Bienias J, Tangney C, Hebert L, Scherr P, Schneider J. Dietary folate  
632 and vitamin B12 intake and cognitive decline among community-dwelling older persons.  
633 *Arch Neurol* 2005; 62:641–5.
- 634 61. Kim Y-I. Folate and cancer: a tale of Dr. Jekyll and Mr. Hyde? *Am J Clin Nutr* 2018;  
635 107:139–42.
- 636 62. Arendt JFH, Sørensen HT, Horsfall LJ, Petersen I. Elevated vitamin B12 levels and cancer  
637 risk in UK primary care: a THIN Database cohort study. *Cancer Epidemiol Biomarkers  
638 Prev* 2019; 28:814–21.
- 639 63. Arendt JFH, Farkas DK, Pedersen L, Nexø E, Sørensen HT. Elevated plasma vitamin B12  
640 levels and cancer prognosis: a population-based cohort study. *Cancer Epidemiol* 2016;  
641 40:158–65.
- 642 64. Son P, Lewis L. Hyperhomocysteinemia [Internet]. In: StatPearls. Treasure Island (FL):  
643 StatPearls Publishing; 2024 [cited 2024 Dec 2]. Available from:  
644 <http://www.ncbi.nlm.nih.gov/books/NBK554408/>
- 645 65. Buuren S van, Groothuis-Oudshoorn K. mice: multivariate imputation by chained equations  
646 in R. *Journal of Statistical Software* 2011; 45:1–67.
- 647 66. R Core Team. R: a language and environment for statistical computing [Internet]. Vienna,  
648 Austria: R Foundation for Statistical Computing; 2015. Available from: [https://www.r-](https://www.r-project.org/)  
649 [project.org/](https://www.r-project.org/)
- 650 67. Lachat C, Hawwash D, Ocké MC, Berg C, Forsum E, Hörnell A, Larsson C, Sonestedt E,  
651 Wirfält E, Åkesson A, et al. Strengthening the Reporting of Observational Studies in  
652 Epidemiology-Nutritional Epidemiology (STROBE-nut): An Extension of the STROBE  
653 Statement. *PLoS Med* 2016; 13:e1002036.

- 654 68. National Institutes of Health. Folate: Dietary Supplement Fact Sheet [Internet]. 2016 [cited  
655 2016 May 5]. Available from: <https://ods.od.nih.gov/factsheets/Folate-HealthProfessional/>
- 656 69. Cardenas A, Ecker S, Fadadu RP, Huen K, Orozco A, McEwen LM, Engelbrecht H-R,  
657 Gladish N, Kobor MS, Rosero-Bixby L, et al. Epigenome-wide association study and  
658 epigenetic age acceleration associated with cigarette smoking among Costa Rican adults.  
659 *Sci Rep* 2022; 12:4277.
- 660 70. Wang M, Li Y, Lai M, Nannini DR, Hou L, Joehanes R, Huan T, Levy D, Ma J, Liu C.  
661 Alcohol consumption and epigenetic age acceleration across human adulthood. *Aging*  
662 (Albany NY) 2023; 15:10938–71.
- 663 71. Carter A, Bares C, Lin L, Reed BG, Bowden M, Zucker RA, Zhao W, Smith JA, Becker  
664 JB. Sex-specific and generational effects of alcohol and tobacco use on epigenetic age  
665 acceleration in the Michigan longitudinal study. *Drug and Alcohol Dependence Reports*  
666 2022; 4:100077.
- 667 72. Liu D, Fang C, Wang J, Tian Y, Zou T. Association between homocysteine levels and  
668 mortality in CVD: a cohort study based on NHANES database. *BMC Cardiovasc Disord*  
669 2024; 24:652.
- 670 73. Liabeuf S, Lenglet A, Desjardins L, Neiryneck N, Glorieux G, Lemke H-D, Vanholder R,  
671 Diouf M, Choukroun G, Massy ZA. Plasma beta-2 microglobulin is associated with  
672 cardiovascular disease in uremic patients. *Kidney International* 2012; 82:1297–303.
- 673 74. Ferguson TW, Komenda P, Tangri N. Cystatin C as a biomarker for estimating glomerular  
674 filtration rate. *Curr Opin Nephrol Hypertens* 2015; 24:295.
- 675 75. Egea V, Zahler S, Rieth N, Neth P, Popp T, Kehe K, Jochum M, Ries C. Tissue inhibitor of  
676 metalloproteinase-1 (TIMP-1) regulates mesenchymal stem cells through let-7f microRNA  
677 and Wnt/ $\beta$ -catenin signaling. *PNAS* 2012; 109:E309–16.
- 678 76. Schoeps B, Frädrieh J, Krüger A. Cut loose TIMP-1: an emerging cytokine in  
679 inflammation. *Trends Cell Biol* 2023; 33:413–26.
- 680 77. Wong HK, Cheung TT, Cheung BMY. Adrenomedullin and cardiovascular diseases. *JRSM*  
681 *Cardiovasc Dis* 2012; 1:cvd.2012.012003.
- 682 78. Farrell C-JL, Kirsch S, Herrmann M. Red cell or serum folate: what to do in clinical  
683 practice? *Clin Chem Lab Med* 2013; 51:555–69.
- 684 79. Aslinia F, Mazza J, Yale S. Megaloblastic anemia and other causes of macrocytosis. *Clin*  
685 *Med Res* 2006; 4:236–41.
- 686 80. Lippi G, Targher G, Montagnana M, Salvagno G, Zoppini G, Guidi G. Relation between  
687 red blood cell distribution width and inflammatory biomarkers in a large cohort of  
688 unselected outpatients. *Arch Pathol Lab Med* 2009; 133:628–32.

- 689 81. Namazi G, Heidar Beygi S, Vahidi MH, Asa P, Bahmani F, Mafi A, Raygan F.  
690 Relationship between red cell distribution width and oxidative stress indexes in patients  
691 with coronary artery disease. *Rep Biochem Mol Biol* 2023; 12:241–50.
- 692 82. Karsten E, Herbert BR. The emerging role of red blood cells in cytokine signalling and  
693 modulating immune cells. *Blood Rev* 2020; 41:100644.
- 694 83. Nwanaji-Enwerem J, Colicino E, Gao X, Wang C, Vokonas P, Boyer E, Baccarelli A,  
695 Schwartz J. Associations of plasma folate and vitamin B6 with blood DNA methylation  
696 age: an analysis of one-carbon metabolites in the VA Normative Aging Study. *J Gerontol A*  
697 *Biol Sci Med Sci* 2021; 76:760–9.
- 698 84. Zhang Q, Vallerga CL, Walker RM, Lin T, Henders AK, Montgomery GW, He J, Fan D,  
699 Fowdar J, Kennedy M, et al. Improved precision of epigenetic clock estimates across  
700 tissues and its implication for biological ageing. *Genome Med* 2019; 11:54.
- 701 85. Belsky DW, Caspi A, Corcoran DL, Sugden K, Poulton R, Arseneault L, Baccarelli A,  
702 Chamarti K, Gao X, Hannon E, et al. DunedinPACE, a DNA methylation biomarker of the  
703 pace of aging. *eLife* 2022; 11:e73420.
- 704 86. Holmes HE, Valentin RE, Jernerén F, de Jager Loots CA, Refsum H, Smith AD, Guarente  
705 L, Dellinger RW, Sampson D. Elevated homocysteine is associated with increased rates of  
706 epigenetic aging in a population with mild cognitive impairment. *Aging Cell* 2024;  
707 23:e14255.
- 708 87. Wald DS, Bishop L, Wald NJ, Law M, Hennessy E, Weir D, McPartlin J, Scott J.  
709 Randomized trial of folic acid supplementation and serum homocysteine levels. *Archives of*  
710 *Internal Medicine* 2001; 161:695–700.
- 711 88. van Oort FVA, Melse-Boonstra A, Brouwer IA, Clarke R, West CE, Katan MB, Verhoef P.  
712 Folic acid and reduction of plasma homocysteine concentrations in older adults: a dose-  
713 response study. *Am J Clin Nutr* 2003; 77:1318–23.
- 714 89. Anderson CAM, Jee SH, Charleston J, Narrett M, Appel LJ. Effects of folic acid  
715 supplementation on serum folate and plasma homocysteine concentrations in older adults: a  
716 dose-response trial. *Am J Epidemiol* 2010; 172:932–41.
- 717 90. Albert CM, Cook NR, Gaziano JM, Zaharris E, MacFadyen J, Danielson E, Buring JE,  
718 Manson JE. Effect of folic acid and B vitamins on risk of cardiovascular events and total  
719 mortality among women at high risk for cardiovascular disease: a randomized trial. *JAMA*  
720 2008; 299:2027–36.
- 721 91. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG,  
722 Wang C-H, Stampfer M. Lowering homocysteine in patients with ischemic stroke to  
723 prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for  
724 Stroke Prevention (VISP) randomized controlled trial. *JAMA* 2004; 291:565–75.

- 725 92. Wang Y, Jin Y, Wang Y, Li L, Liao Y, Zhang Y, Yu D. The effect of folic acid in patients  
726 with cardiovascular disease: a systematic review and meta-analysis. *Medicine* 2019;  
727 98:e17095.
- 728 93. Li Y, Huang T, Zheng Y, Muka T, Troup J, Hu FB. Folic acid supplementation and the risk  
729 of cardiovascular diseases: a meta-analysis of randomized controlled trials. *J Am Heart*  
730 *Assoc* 2016; 5:e003768.
- 731 94. Durga J, van Boxtel MPJ, Schouten EG, Kok FJ, Jolles J, Katan MB, Verhoef P. Effect of  
732 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a  
733 randomised, double blind, controlled trial. *Lancet* 2007; 369:208–16.
- 734 95. Ford AH, Flicker L, Alfonso H, Thomas J, Clarnette R, Martins R, Almeida OP. Vitamins  
735 B12, B6, and folic acid for cognition in older men. *Neurology* 2010; 75:1540–7.
- 736 96. van Soest APM, van de Rest O, Witkamp RF, de Groot LCPGM. Positive effects of folic  
737 acid supplementation on cognitive aging are dependent on  $\omega$ -3 fatty acid status: a post hoc  
738 analysis of the FACIT trial. *Am J Clin Nutr* 2021; 113:801–9.
- 739 97. Biomarkers of Aging Consortium, Herzog CMS, Goeminne LJE, Poganik JR, Barzilai N,  
740 Belsky DW, Betts-LaCroix J, Chen BH, Chen M, Cohen AA, et al. Challenges and  
741 recommendations for the translation of biomarkers of aging. *Nat Aging* 2024; 4:1372–83.
- 742  
743

744 **Tables**

745

746 **Table 1: Participant characteristics (N = 2,346).**

747

	<b>n (%) or mean (SD)</b>
Male, n (%)	1,202 (51.2%)
Age at screening, mean (SD)	65.1 (9.3)
Race and ethnicity, n (%)	
Mexican American	681 (29.0%)
Other Hispanic	151 (6.4%)
Non-Hispanic White	922 (39.3%)
Non-Hispanic Black	511 (21.8%)
Other race and Multiracial	81 (3.5%)
BMI (kg/m <sup>2</sup> ), mean (SD)	28.8 (5.8)
Missing, n (%)	84 (3.6%)
Smoking status, n (%)	
Current	374 (15.9%)
Former	903 (38.5%)
Never	1,063 (45.3%)
Missing	6 (0.3%)
Alcohol intake, drinks/day, mean (SD)	0.4 (1.0)
Missing, n (%)	111 (5.0%)
Serum folate (ng/mL), mean (SD)	16.5 (12.2)
Missing, n (%)	1 (<0.01%)
Folate deficiency <sup>a</sup>	5 (<0.01%)
Red blood cell folate (ng/mL RBC), mean (SD)	328 (159)
Missing, n (%)	5 (0.2%)
Vitamin B12 (pg/mL), mean (SD)	734 (4,840)
Missing, n (%)	1 (0.0%)
Vitamin B12 insufficiency, n (%) <sup>b</sup>	329 (14.0%)
Vitamin B12 deficiency, n (%) <sup>c</sup>	21 (0.9%)
Homocysteine (umol/L), mean (SD)	10.1 (5.87)
Missing, n (%)	3 (0.1%)
Hyperhomocysteinemia <sup>d</sup>	192 (8.2%)
Methylmalonic acid (umol/L), mean (SD)	0.2 (0.8)
Missing, n (%)	7 (0.3%)

a. Serum folate ≤ 3 ng/mL. b. B12 < 300 pg/mL. c. < 150 pg/mL. d. > 15 umol/L.

748

749

750 **Table 2: Associations of serum folate, red blood cell (RBC) folate, and homocysteine with**  
 751 **GrimAge2 components and measured proteins.** Effect estimates (95% confidence intervals (CIs)) and  
 752 *p*-values are shown for a doubling in homocysteine concentration. GrimAge2 components are expressed  
 753 on a Z-score scale. Results are from weighted generalized linear regression models adjusted for age, age<sup>2</sup>,  
 754 sex, race and ethnicity, BMI, smoking status, alcohol intake, education level, occupation, and poverty to  
 755 income ratio  
 756

	<i>GrimAge2 component</i>			<i>Direct Measurement</i>		
	<i>B</i>	<i>95% CI</i>	<i>p</i>	<i>B</i>	<i>95% CI</i>	<i>p</i>
<b>Serum Folate<sup>a</sup></b>						
GDF15	0.00	(-0.06, 0.05)	0.92	0.02 <sup>d</sup>	(-0.07, 0.11)	0.66
B2M	-0.04	(-0.12, 0.04)	0.25	0.04 <sup>e</sup>	(-0.03, 0.12)	0.22
Cystatin C	-0.01	(-0.06, 0.04)	0.68			
TIMP1	-0.02	(-0.05, 0.02)	0.30			
ADM	-0.05	(-0.13, 0.03)	0.21			
PAI1	0.03	(-0.07, 0.13)	0.52			
Leptin	-0.01	(-0.04, 0.03)	0.69			
log(CRP)	-0.01	(-0.14, 0.11)	0.84	-0.08 <sup>f</sup>	(-0.22, 0.06)	0.23
log(Hemoglobin A1C)	0.00	(-0.07, 0.06)	0.90	0.01 <sup>g</sup>	(0.00, 0.02)	0.12
Smoking pack years	<b>-0.07</b>	<b>(-0.13, -0.01)</b>	<b>0.033</b>			
<b>RBC Folate<sup>b</sup></b>						
GDF15	<b>0.07</b>	<b>(0.01, 0.13)</b>	<b>0.023</b>			
B2M	0.02	(-0.06, 0.1)	0.57	0.11 <sup>d</sup>	(0.00, 0.22)	0.06
Cystatin C	0.05	(-0.02, 0.12)	0.12	<b>0.11<sup>e</sup></b>	<b>(0.01, 0.21)</b>	<b>0.029</b>
TIMP1	0.04	(0.00, 0.09)	0.06			
ADM	0.05	(-0.03, 0.14)	0.21			
PAI1	<b>0.14</b>	<b>(0.01, 0.27)</b>	<b>0.038</b>			
Leptin	0.07	(0.00, 0.13)	0.06			
log(CRP)	<b>0.23</b>	<b>(0.11, 0.35)</b>	<b>0.002</b>	0.19 <sup>f</sup>	(-0.01, 0.38)	0.06
log(Hemoglobin A1C)	0.03	(-0.08, 0.14)	0.51	-0.01 <sup>g</sup>	(-0.03, 0.01)	0.35
Smoking pack years	0.00	(-0.10, 0.09)	0.95			
<b>Homocysteine<sup>c</sup></b>						
GDF15	0.04	(-0.09, 0.17)	0.55		-	
B2M	<b>0.14</b>	<b>(0.06, 0.22)</b>	<b>0.002</b>	<b>0.39<sup>d</sup></b>	<b>(0.29, 0.49)</b>	<b>&lt;0.001</b>
Cystatin C	<b>0.09</b>	<b>(0.02, 0.16)</b>	<b>0.021</b>	<b>0.32<sup>e</sup></b>	<b>(0.24, 0.39)</b>	<b>&lt;0.001</b>
TIMP1	<b>0.08</b>	<b>(0.03, 0.13)</b>	<b>0.005</b>		-	
ADM	<b>0.17</b>	<b>(0.06, 0.29)</b>	<b>0.007</b>		-	
PAI1	0.10	(-0.05, 0.24)	0.18		-	
Leptin	0.00	(-0.07, 0.08)	0.99		-	
log(CRP)	0.14 <sup>a</sup>	(-0.02, 0.29)	0.09	-0.13 <sup>f</sup>	(-0.37, 0.11)	0.28
log(Hemoglobin A1C)	0.09 <sup>a</sup>	(-0.04, 0.22)	0.17	<b>-0.04<sup>g</sup></b>	<b>(-0.06, -0.02)</b>	<b>0.002</b>
Smoking pack years	<b>0.15</b>	<b>(0.02, 0.28)</b>	<b>0.030</b>			

a. *N* = 1,832 for GrimAge2 components; *N* = 1,812 for B2M concentration; *N* = 1,816 for cystatin C concentration; *N* = 1,832 for CRP concentration; *N* = 1,832 for hemoglobin A1C concentration.

b. *N* = 1,830 for GrimAge2 components; *N* = 1,813 for B2M concentration; *N* = 1,815 for cystatin C concentration; *N* = 1,830 for CRP concentration; *N* = 1,830 for hemoglobin A1C concentration.

c. *N* = 1,830 for GrimAge2 components; *N* = 1,812 for B2M concentration; *N* = 1,816 for cystatin C concentration; *N* = 1,830 for CRP concentration; *N* = 1,830 for hemoglobin A1C concentration.

d. log<sub>2</sub>(serum B2M in mg/L). e. log<sub>2</sub>(serum cystatin C in mg/L). f. log<sub>2</sub>(CRP in mg/dL). g. log<sub>2</sub>(plasma hemoglobin A1C %).

757

758 **Figure legends**

759

760 **Figure 1:** One-carbon metabolism. Compounds included in this study are shown in orange.

761

762 **Figure 2: Associations of promoters of one-carbon metabolism (OCM) with epigenetic aging**  
763 **biomarkers.** Effect estimates (95% confidence intervals (CIs)) and  $p$ -values are shown for a doubling in  
764 concentration of each compound. Results are from weighted generalized linear regression models  
765 adjusted for age, age<sup>2</sup>, sex, race and ethnicity, BMI, education level, occupation, and poverty to income  
766 ratio. Effect estimates for Horvath1, Horvath2, Hannum, PhenoAge, and GrimAge2 EAD are in years;  
767 effect estimates for DunedinPoAm are in standard deviations; and effect estimates for DNAmTL EAD are  
768 in kilobases. RBC = red blood cell; EAD = epigenetic age deviation. \*  $p < 0.05$ ; \*\*  $p < 0.01$ ; \*\*\*  $p <$   
769 0.001.

770


771 **Figure 3: Associations of markers of one-carbon metabolism (OCM) deficiencies with epigenetic**  
772 **aging biomarkers.** Effect estimates (95% confidence intervals (CIs)) and  $p$ -values are shown for a  
773 doubling in concentration of each OCM-related compound. Results are from weighted generalized linear  
774 regression models adjusted for age, age<sup>2</sup>, sex, race and ethnicity, BMI, education level, occupation, and  
775 poverty to income ratio. Effect estimates for Horvath1, Horvath2, Hannum, PhenoAge, and GrimAge2  
776 EAD are in years; effect estimates for DunedinPoAm are in standard deviations; and effect estimates for  
777 DNAmTL EAD are in kilobases. EAD = epigenetic age deviation; MMA = methylmalonic acid. \*  $p <$   
778 0.05; \*\*  $p < 0.01$ ; \*\*\*  $p < 0.001$ .

779


780 **Figure 4: Scatter plots and associations of homocysteine concentration with GrimAge2 epigenetic**  
781 **age deviation (EAD).** The transparency of points corresponds to their survey weights. Estimates are from  
782 weighted generalized linear regression models and shown for average age, BMI, alcohol intake, and  
783 poverty to income ratio, and for the reference level of race and ethnicity, education level, and occupation.  
784 Interaction  $p$ -value for never smokers vs. former smokers = 0.27. \*  $p < 0.05$ ; \*\*  $p < 0.01$ .

785










Base model




Adjusted for smoking status and alcohol intake




### Base model



Homocysteine





### Adjusted for smoking status and alcohol intake



MMA



**Never smokers****Former smokers****Current smokers**